In vitro comparison of harvesting site effects on cardiac extracellular matrix hydrogels
Source abstract
Abstract
Abstract Cardiac extracellular matrix (cECM) derived hydrogel has been investigated to treat myocardial infarction through animal studies and clinical trials. The tissue harvesting site commonly selects porcine left ventricle (LV) because heart attack majorly takes place in LV. However, little is known about whether the region of cardiac tissue harvesting is critical for downstream applications. In this work, in vitro studies to compare cECM hydrogels derived from adult porcine whole heart (WH), LV, and right ventricle (RV) were performed. The cECM from WH has similar chemical composition compared with cECM from LV and RV. All three types of cECM hydrogels share many similarities in terms of their microstructure, gelation time, and mechanical properties. WH‐derived cECM hydrogels have larger variations in storage modulus (G′) and complex modulus (G*) compared with the other two types of cECM hydrogels. Both human cardiomyocytes and mesenchymal stem cells could maintain high cell viability on all hydrogels without significant difference. In terms of above results, the cECM hydrogels from WH, LV and RV exhibited similarity in material properties and cell response in vitro. Thus, future fabrication of cECM hydrogels from WH would increase the yield, which would decrease processing time and production cost.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Tissue Engineering and Regenerative Medicine · Electrospun Nanofibers in Biomedical Applications · Cardiac Structural Anomalies and Repair
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biomedical Engineering The University of Akron Ohio USA
Department of Bioengineering University of Texas at Arlington Arlington Texas USA
Department of Bioengineering Northeastern University Boston Massachusetts USA
Department of Chemical Engineering Northeastern University Boston Massachusetts USA
Funding
American Heart Association · National Heart, Lung, and Blood Institute
References (43)
Show source-provided references
1. 10.1172/JCI8749110.1172/JCI87491 ↗
2. 10.1126/scitranslmed.300550310.1126/scitranslmed.3005503 ↗
3. 10.1016/j.biomaterials.2017.03.01610.1016/j.biomaterials.2017.03.016 ↗
4. 10.1016/j.actbio.2016.12.01510.1016/j.actbio.2016.12.015 ↗
5. 10.3727/096368915X68979410.3727/096368915X689794 ↗
6. 10.1016/j.jacbts.2019.07.01210.1016/j.jacbts.2019.07.012 ↗
7. 10.1016/j.actbio.2016.11.06810.1016/j.actbio.2016.11.068 ↗
8. Acellular porcine heart matrices: whole organ decellularization with 3D‐bioscaffold & vascular preservation
9. 10.1021/acsami.9b0645310.1021/acsami.9b06453 ↗
10. 10.1016/j.biomaterials.2009.06.04510.1016/j.biomaterials.2009.06.045 ↗
11. 10.1016/j.biomaterials.2012.06.05110.1016/j.biomaterials.2012.06.051 ↗
12. 10.1016/0304-4165(86)90306-510.1016/0304-4165(86)90306-5 ↗
13. 10.1016/0003-9861(61)90291-010.1016/0003-9861(61)90291-0 ↗
14. 10.1021/acsami.5b0319510.1021/acsami.5b03195 ↗
15. 10.1089/biores.2014.004610.1089/biores.2014.0046 ↗
16. 10.1016/j.biomaterials.2010.07.08310.1016/j.biomaterials.2010.07.083 ↗
17. 10.1016/j.ymeth.2015.03.02410.1016/j.ymeth.2015.03.024 ↗
18. Human versus porcine tissue sourcing for an injectable myocardial matrix hydrogel
19. 10.1007/s13346-018-00601-210.1007/s13346-018-00601-2 ↗
20. 10.1007/s10856-018-6135-410.1007/s10856-018-6135-4 ↗
21. 10.1016/j.jacc.2011.10.88810.1016/j.jacc.2011.10.888 ↗
22. 10.1016/1054-8807(94)90012-410.1016/1054-8807(94)90012-4 ↗
23. 10.1016/j.actbio.2015.01.02710.1016/j.actbio.2015.01.027 ↗
24. 10.1016/j.actbio.2012.06.03010.1016/j.actbio.2012.06.030 ↗
25. 10.1007/s10616-015-9895-410.1007/s10616-015-9895-4 ↗
26. 10.1007/s40778-016-0056-210.1007/s40778-016-0056-2 ↗
27. 10.1016/j.bbagen.2014.01.01010.1016/j.bbagen.2014.01.010 ↗
28. 10.1088/0957-4484/22/49/49401510.1088/0957-4484/22/49/494015 ↗
29. 10.1002/mabi.20180007910.1002/mabi.201800079 ↗
30. 10.1002/adhm.20180121710.1002/adhm.201801217 ↗
31. 10.1016/j.devcel.2017.12.02410.1016/j.devcel.2017.12.024 ↗
32. 10.1002/mabi.20100042310.1002/mabi.201000423 ↗
33. 10.1039/C5TB02564H10.1039/C5TB02564H ↗
34. 10.1038/s41536-018-0044-510.1038/s41536-018-0044-5 ↗
35. 10.1016/j.stem.2013.05.00810.1016/j.stem.2013.05.008 ↗
36. 10.3390/bioengineering502002810.3390/bioengineering5020028 ↗
37. 10.1016/j.bioactmat.2020.01.00310.1016/j.bioactmat.2020.01.003 ↗
38. 10.1007/978-1-4939-1047-2_710.1007/978-1-4939-1047-2_7 ↗
39. 10.1007/s12265-011-9304-010.1007/s12265-011-9304-0 ↗
40. Culturing on decellularized extracellular matrix enhances antioxidant properties of human umbilical cord‐derived mesenchymal stem cells
41. 10.1021/acsbiomaterials.9b0006410.1021/acsbiomaterials.9b00064 ↗
42. 10.1155/2019/670843510.1155/2019/6708435 ↗
43. 10.1016/j.bbamcr.2019.11855910.1016/j.bbamcr.2019.118559 ↗